Your browser doesn't support javascript.
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
Cohen, Jeffrey A; Bermel, Robert A; Grossman, Cynthia I; Hersh, Carrie M; Hyland, Megan; Mowry, Ellen M; Naismith, Robert; Naylor, Maria L; Nicholas, Jacqueline; Rajbhandar, Rajani; Singh, Carol M; Tintorè, Mar; Zabalza, Ana; Ziemssen, Tjalf; Williams, James R; Montalban, Xavier.
  • Cohen JA; Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Bermel RA; Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Grossman CI; Biogen, Cambridge, MA, USA.
  • Hersh CM; Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA.
  • Hyland M; Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
  • Mowry EM; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Naismith R; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
  • Naylor ML; Biogen, Cambridge, MA, USA.
  • Nicholas J; OhioHealth Multiple Sclerosis Center, Riverside Methodist Hospital, Columbus, OH, USA.
  • Rajbhandar R; Biogen, Cambridge, MA, USA.
  • Singh CM; Biogen, Cambridge, MA, USA.
  • Tintorè M; Centre d'Esclerosi Múltiple de Catalunya, Department of Neurology and Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Zabalza A; Centre d'Esclerosi Múltiple de Catalunya, Department of Neurology and Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Ziemssen T; Multiple Sclerosis Center Dresden, Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl-Gustav Carus, Dresden, Germany.
  • Williams JR; Biogen, Cambridge, MA, USA.
  • Montalban X; Centre d'Esclerosi Múltiple de Catalunya, Department of Neurology and Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Mult Scler ; 28(7): 1131-1137, 2022 06.
Article in English | MEDLINE | ID: covidwho-1861993
ABSTRACT

BACKGROUND:

The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain.

METHODS:

Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response.

RESULTS:

Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group.

CONCLUSION:

Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Topics: Vaccines Limits: Humans Language: English Journal: Mult Scler Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: 13524585211061343

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Topics: Vaccines Limits: Humans Language: English Journal: Mult Scler Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: 13524585211061343